Faculty Opinions recommendation of Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II – Study of the EORTC Soft Tissue and Bone Sarcoma Group

10.1016/j.ejca.2007.01.014 ◽

2007 ◽

Vol 43 (6) ◽

pp. 1017-1022 ◽

Cited By ~ 18

Author(s):

P. Reichardt ◽

O.S. Nielsen ◽

S. Bauer ◽

J.T. Hartmann ◽

P. Schöffski ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Adult Patients ◽

VP-16 in advanced soft tissue sarcoma: A phase II study of the EORTC soft tissue and bone sarcoma group

European Journal of Cancer and Clinical Oncology ◽

10.1016/0277-5379(87)90324-5 ◽

1987 ◽

Vol 23 (5) ◽

pp. 579-580 ◽

Cited By ~ 19

Author(s):

P. Dombernowsky ◽

J. Buesa ◽

H.M. Pinedo ◽

A. Santoro ◽

H. Mouridsen ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group

10.1016/0959-8049(92)90132-l ◽

1992 ◽

Vol 28 (4-5) ◽

pp. 855-857 ◽

Cited By ~ 6

Author(s):

R. Somers ◽

A. Santoro ◽

J. Verweij ◽

P. Lucas ◽

J. Rouëssé ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

9403 Eribulin mesylate (E7389) in patients with leiomyosarcoma (LMS) and other (OTH) subtypes of soft tissue sarcoma (STS): a Phase II study from the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC 62052)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71991-3 ◽

2009 ◽

Vol 7 (2) ◽

pp. 591

Author(s):

P. Schöffski ◽

J.T. Hartmann ◽

P. Hohenberger ◽

A. Krarup-Hansen ◽

J. Wanders ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Eribulin Mesylate ◽

European Organisation

Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC soft tissue and bone sarcoma cooperative group

European Journal of Cancer and Clinical Oncology ◽

10.1016/0277-5379(87)90129-5 ◽

1987 ◽

Vol 23 (9) ◽

pp. 1413-1414 ◽

Cited By ~ 6

Author(s):

J.G. Rouëssé ◽

A.T. van Oosterom ◽

P. Capellaere ◽

P. Kerbrat ◽

C.J. van Coninge ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Cooperative Group ◽

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

10.1016/s0959-8049(98)00403-1 ◽

1999 ◽

Vol 35 (3) ◽

pp. 410-412 ◽

Cited By ~ 52

Author(s):

P.J Woll ◽

I Judson ◽

S.M Lee ◽

S Rodenhuis ◽

O.S Nielsen ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Adult Patients ◽

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

10.1016/j.ejca.2006.09.014 ◽

2007 ◽

Vol 43 (2) ◽

pp. 308-315 ◽

Cited By ~ 35

Author(s):

Michael Leahy ◽

Isabelle Ray-Coquard ◽

Jaap Verweij ◽

Axel Le Cesne ◽

Florence Duffaud ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

European Organisation ◽

Metastatic Soft Tissue Sarcoma ◽

Potential Activity

Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and Bone Sarcoma Group

European Journal of Cancer and Clinical Oncology ◽

10.1016/0277-5379(85)90037-9 ◽

1985 ◽

Vol 21 (4) ◽

pp. 459-461 ◽

Cited By ~ 7

Author(s):

A.T van Oosterom ◽

A Santoro ◽

V Bramwell ◽

M Davy ◽

H.T Mouridsen ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Mitomycin C ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Exatecan (DX-8951f), a new topoisomerase I - inhibitor, is inactive in heavily pretreated patients (pts.) with advanced soft tissue sarcoma (STS): A phase II - study of the EORTC Soft Tissue and Bone Sarcoma Group

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.9058 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 9058-9058

Author(s):

D. Pink ◽

P. Reichardt ◽

O. S. Nielsen ◽

S. Bauer ◽

J. T. Hartmann ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Topoisomerase I ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Advanced Soft Tissue Sarcoma ◽

Topoisomerase I Inhibitor ◽

Heavily Pretreated ◽

Pretreated Patients

Faculty Opinions recommendation of Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718556209.793500073 ◽

2014 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Antitumor Activity ◽

Phase Ii ◽

Phase Ii Study ◽